Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Transl Med. 2022 May 10;20(1):200. doi: 10.1186/s12967-022-03406-7.
The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2-4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bispecific antibodies, mitogen-activated protein kinase (MAPK) inhibitors versus immunotherapy in the adjuvant setting, whether the use of corticosteroids for the management of side effects have an impact on outcomes, the choice of programmed death (PD)-1 combination therapy with cytotoxic T-lymphocyte-associated antigen (CTLA)-4 or lymphocyte-activation gene (LAG)-3, whether radiation is needed for brain metastases, when lymphadenectomy should be integrated into the treatment plan and then the last debate, telemedicine versus face-to-face. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. Audiences voted both before and after each debate.
2021 年黑色素瘤桥接虚拟大会（12 月 2 日至 4 日）的大辩论环节邀请了七位黑色素瘤领域的专家就七个重要问题进行了辩论。辩论内容涉及过继细胞疗法与双特异性抗体的应用、辅助治疗中丝裂原活化蛋白激酶（MAPK）抑制剂与免疫疗法的比较、皮质类固醇用于治疗副作用是否会影响结果、程序性死亡（PD）-1 联合细胞毒性 T 淋巴细胞相关抗原（CTLA）-4 或淋巴细胞激活基因（LAG）-3 的选择、脑转移是否需要放疗、何时将淋巴结清扫术纳入治疗计划，最后一个辩论是远程医疗与面对面医疗的比较。与之前的 Bridge 大会一样，辩论是由会议主席分配的，专家在辩论中的立场不一定反映了他们各自的个人观点。观众在每次辩论前后都进行了投票。
